tapebrief
INCY · Q2 2025

INCY · Q3 2025 Earnings

Bullish

Incyte

Reported October 28, 2025

30-second summary

Revenue grew 20% YoY to $1.37B with Jakafi +7% to $791M and Opzelura +35% to $188M. Incyte raised Jakafi FY guide to $3.050–3.075B (from $3.00–3.05B), Other Hematology/Oncology to $550–575M (from $500–520M), and the headline FY total net product revenue range to $4.23–4.32B — while leaving Opzelura at $630–670M for the second consecutive quarter. That is the tell: management does not yet trust the topical's 1H momentum to extrapolate. The new $4.23–4.32B headline is a tighter, higher anchor on the same underlying trajectory described last quarter.

Headline numbers

EPS

Q3 FY2025

$2.26

Revenue

Q3 FY2025

$1.37B

+20.0% YoY

Gross margin

Q3 FY2025

91.4%

Operating margin

Q3 FY2025

32.5%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$1.37B+20.0%$1.22B+12.3%
EPS$2.26—$1.57+43.9%
Gross margin91.4%———
Operating margin32.5%—43.6%-1110bps

Guidance

Incyte significantly raised full-year 2025 net product revenue guidance to $4.23–$4.32B (from $3.00–$3.05B), a 40%+ uplift, driven by stronger-than-expected demand for Jakafi and other hematology-oncology products, while reaffirming Opzelura guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Net Product Revenue
FY 2025
$3.00 - $3.05 billion$4.23 - $4.32 billion+$1.23 - $1.27 billion (40.4% - 42.3% increase in guidance range)Raised
Jakafi Net Product Revenue
FY 2025
Not explicitly stated in prior full-year guide$3.050 - $3.075 billionRaised; prior guidance implied lower contributionRaised
Other Hematology and Oncology Marketed Products
FY 2025
$500 - $520 million (as 'Other Oncology')$550 - $575 million+$50 - $55 million (9.6% - 11.0% increase)Raised

Reaffirmed unchanged this quarter: Opzelura Net Product Revenue ($630 - $670 million)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Jakafi$0.791B+7.0%
Opzelura$0.188B+35.0%
Iclusig$0.038B+26.0%
Minjuvi/Monjuvi$0.042B+34.0%
Jakafi Net Product Revenue (Q3 2025)$791 million—
Opzelura Net Product Revenue (Q3 2025)$188 million—
Net Product Revenue Growth (YoY)19%—
Total Revenue Growth (YoY)20%—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Non-GAAP Operating Margin36.5%
Cash and Marketable Securities$2.9 billion

Management tone

Narrative arc: Q2 "CEO repositioning around MPN dominance" → Q3 "commercial execution validating the reposition, and pipeline pruning starting to bite." The Q2 brief flagged Meury's framing as the news; one quarter later the operating results — Jakafi raise number two, Other Oncology raise number two, Niktimvo +27% QoQ — are the substrate that lets that framing harden into guidance. Meury's prepared remarks frame the 2026 budget around three rules: "ring fence" strategic growth drivers, control costs in low-value areas, and bank or reallocate the savings. Pablo paired that with concrete pipeline subtractions — BET inhibitor (INCB57643), anti-CD122 (INCA34460), and povorcitinib in CSU all paused or stopped — under explicit go/no-go criteria.

The capital allocation language has tightened from Q2's broader BD posture into specific gating: ruxolitinib XR bioequivalence submission to FDA in Q4, EU Type-II variation filing for ruxolitinib cream 1.5% in adult AD by year-end, and the 989 mutCALR Phase 1 readout in 2H 2025. Each is a binary near-term marker against which next quarter's brief can be judged.

Opzelura is the one place where tone and data are now visibly out of step. Management is still printing +35%, yet has reaffirmed the same $630–670M range twice. Either the September pediatric approval and EU expansion are not contributing as much as the franchise narrative implies, or Q4 will force a third revision. The flat guide through two quarters of acceleration is the single most interesting disclosure in this release.

Recurring themes management leaned on this quarter:

Targeted therapy shift in MPNs (989 as first mutation-specific therapy)Multi-indication portfolio expansion (Povacitinib across HS/vitiligo/PN; Opsalura international growth)Solid tumor pipeline de-risking (TGF-beta/PD-1, KRAS G12D showing encouraging Phase I data)Nictimbo rapid adoption and durability (90% BMT penetration, 80% retention at 9 months)Strategic cost discipline and pipeline prioritization (pausing/stopping lower-value programs)Long-duration revenue streams post-Jakifi LOE (989, Povacitinib, solid tumors as foundational)

Risks management surfaced:

Launch unpredictability and quarterly volatility for early-stage productsRegulatory uncertainty on novel endpoints for 989 in MPNsCompetitive intensity in dermatology (branded non-sterile topicals expanding at 20% rate)JAK inhibitor class-wide risk profile complicating BET inhibitor development decisionsFrontline GVHD pathway complexity (steroid-free regimen and combo trials carry execution risk)

Answers to last quarter's watch list

Opzelura FY guide: Q3 printed $188M (+35% YoY) and management reaffirmed $630–670M for the second straight quarter. YTD Opzelura is $471M (disclosed nine-month figure), meaning Q4 needs $159–199M to hit the range — well within run-rate. The reaffirmation is now a stance, not an oversight. Status: Resolved negatively (for the raise thesis; the bull case requires Q4 to force the issue)
Niktimvo trajectory vs. Rezurock analog: $46M in Q3 vs $36M in Q2 — +27% QoQ. The Other Heme/Onc guide raise to $550–575M (from $500–520M) is the bundled validation. The analog is intact.
Resolved positively
989 MF readout cadence: Press release reiterates the 2H 2025 Phase 1 readout; the call clarified that ET pivotal start lands in 1H 2026 and MF pivotal start in 2H 2026.
Continue monitoring
Jakafi paid demand: +7% in Q3 vs +8% in Q2 — modest deceleration, but paid demand was disclosed at +10% YoY (inventory was flat), and the FY guide was raised again ($3,050–3,075M from $3,000–3,050M).
Continue monitoring
Other Oncology composition: Iclusig +26%, Minjuvi/Monjuvi +34% — both materially better than Q2 (Iclusig +22%, Monjuvi flat). The mix is improving in exactly the assets the prior brief flagged as not load-bearing.
Resolved positively
Capital allocation signal: Cash grew from $2.4B to $2.9B QoQ; no BD transaction announced. Management committed to a Phase III start for 890 in 1L MSS colorectal cancer in 2026, which absorbs capital internally rather than externally. Pipeline subtractions (BET, anti-CD122, POVO/CSU) tighten the funnel.
Continue monitoring

What to watch into next quarter

989 mutCALR Phase 1 MF readout in 2H 2025: the single most important pipeline catalyst of the year. Watch the monotherapy cohort against the momelotinib bar (SVR35 7–22%, TSS50 ~25–26%), and the three translational endpoints (whole-blood VAF, CD34+ mutCALR cells, bone-marrow mutCALR megakaryocytes).

Opzelura Q4 print: YTD $471M against a $630–670M FY range means $159–199M needed in Q4. Either Q4 forces a raise or the reaffirmation flags a 2H deceleration we haven't yet seen — both outcomes are informative.

Ruxolitinib XR FDA bioequivalence submission: committed for Q4. A slip into 2026 would be the first execution miss of the Meury era.

Niktimvo QoQ trajectory: sequenced $36M → $46M (+27%). A Q4 print at or above $55M sustains the Rezurock analog; below $50M starts to break it.

First BD transaction: cash now $2.9B with no deal yet announced. Therapy area and deal size will calibrate how literally to read the MPN-dominance framing.

2026 OpEx framework: Meury declined to hardcode an R&D-as-%-of-sales target but committed to margin expansion via sales leverage. Watch the Q4 call for the first numbers attached to that framework.

Sources

  1. Incyte Q3 2025 press release, filed with SEC: https://www.sec.gov/Archives/edgar/data/879169/000087916925000115/incy-q32025xexx991.htm
  2. Incyte Q3 2025 earnings call transcript (prepared remarks and Q&A)
  3. Tapebrief Incyte Q2 2025 brief (cross-quarter trajectory and watch list)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.